Skip to main content
. Author manuscript; available in PMC: 2021 Jul 12.
Published in final edited form as: Clin Cancer Res. 2021 Jan 20;27(7):1882–1892. doi: 10.1158/1078-0432.CCR-20-3946

Figure 2.

Figure 2

Pharmacodynamic data for guadecitabine effect with respect to (A, B) dose level cohort within the dose expansion phase and (C, D) randomised treatment allocation within the dose expansion phase for (A, C) mean cfDNA LINE-1 promotor methylation with respect to dose level cohort or treatment arm respectively and (B, D) HbF re-expression status for individual patients and line of best fit (dashed lines, Loess method)